Fractyl Health reports Q4 2024 net loss $25.0M; REMAIN-1 enrollment surges to 189+ patients

FRACTYL HEALTH, INC.

Q4 2024 net loss $25.0M vs $19.2M in Q4 2023; R&D expense rose to $20.3M from $10.1M.
Cash and equivalents $67.5M; cash runway extended into 2026 after pausing T2D Revita programs.
REMAIN-1 pivotal study enrolled >189 patients across 13 sites; midpoint data expected Q2 2025, full enrollment summer 2025.
Rejuva RJVA-001 CTA for T2D submission expected H1 2025; preliminary data (if authorized) in 2026.
Strategic shift: focus Revita on weight maintenance, pause T2D Revita programs (REVITALIZE-1, Germany Registry).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.